1. Home
  2. JPC vs WVE Comparison

JPC vs WVE Comparison

Compare JPC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Preferred & Income Opportunities Fund

JPC

Nuveen Preferred & Income Opportunities Fund

HOLD

Current Price

$7.80

Market Cap

3.0B

Sector

Finance

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.76

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JPC
WVE
Founded
N/A
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.4B
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
JPC
WVE
Price
$7.80
$6.76
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$29.81
AVG Volume (30 Days)
825.0K
3.9M
Earning Date
01-01-0001
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$85.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$7.22
$5.02
52 Week High
$8.30
$21.73

Technical Indicators

Market Signals
Indicator
JPC
WVE
Relative Strength Index (RSI) 39.08 36.66
Support Level $7.22 $5.02
Resistance Level $8.09 $7.65
Average True Range (ATR) 0.06 0.36
MACD -0.02 0.08
Stochastic Oscillator 1.85 8.99

Price Performance

Historical Comparison
JPC
WVE

About JPC Nuveen Preferred & Income Opportunities Fund

Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: